Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults, and annually accounts for the majority of deaths from acute leukemia in the United States. Test your knowledge about the diagnosis of AML in our latest quiz.

Source: CancerNetworkCategory: Cancer & Oncology Authors: Tags: Quiz Source Type: news

Related Links:

Publication date: August 2018Source: Seminars in Cancer Biology, Volume 51Author(s): Linn Gillberg, Andreas D. Ørskov, Minmin Liu, Laurine B.S. Harsløf, Peter A. Jones, Kirsten GrønbækAbstractOver the past few years it has become clear that vitamin C, as a provider of reduced iron, is an essential factor for the function of epigenetic regulators that initiate the demethylation of DNA and histones. Vitamin C deficiency is rare in the general population, but is frequently observed in patients with cancer. Genes encoding epigenetic regulators are often mutated in cancer, underscoring their central r…

We describe the first multicenter prospective study to assess the efficacy, safety, and immune reconstitution of a novel sequential transplant approach in 24 patients with primary induction failure/relapsed acute myeloid leukemia (AML). The sequential regimen consisted of cladribine 5  mg/m2/day and cytarabine 2  g/m2/day for 5  days and mitoxantrone 7 mg/m2/day for 3  days, followed by myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT) using intravenous busulfan (3.2 mg/kg/day) for 4 days and cyclophosphamide (60 mg/kg/day) for 2 days. Patients in CR w…

Publication date: Available online 13 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Marielle Perry, Sarah Bertoli, Clément Rocher, Sandrine Hayette, Sophie Ducastelle, Fiorenza Barraco, Hélène Labussière-Wallet, Gilles Salles, Christian Recher, Xavier Thomas, Etienne PaubelleAbstractBackgroundOutcome of patients with mutation of the FLT3 tyrosine kinase domain (FLT3-TKD) in acute myeloid leukemia (AML) remains controversial.Patients and MethodsHerein, we present a retrospective study of 126 newly diagnosed patients with AML performed in 2 French centers.ResultsFLT3-TKD mutati…

Condition:   Neoplasms Interventions:   Drug: GSK3326595;   Drug: 5-azacitidine;   Drug: Best available care Sponsor:   GlaxoSmithKline Not yet recruiting

Source: ClinicalTrials.govCategory: Research Source Type: clinical trials

Publication date: Available online 2 August 2018Source: The LancetAuthor(s): Nicholas J Short, Michael E Rytting, Jorge E CortesSummaryFor several decades, few substantial therapeutic advances have been made for patients with acute myeloid leukaemia. However, since 2017 unprecedented growth has been seen in the number of drugs available for the treatment of acute myeloid leukaemia, with several new drugs receiving regulatory approval. In addition to advancing our therapeutic armamentarium, an increased understanding of the biology and genomic architecture of acute myeloid leukaemia has led to refined risk assessment of thi…

Source: The LancetCategory: General Medicine Source Type: research

Molecules, Vol. 23, Pages 1938: Styryl Quinazolinones as Potential Inducers of Myeloid Differentiation via Upregulation of C/EBPα
Molecules doi: 10.3390/molecules23081938
Authors:
Radhakrishnan Sridhar
Hisashi Takei
Riyaz Syed
Ikei S. Kobayashi
Liu Bee Hui
Ahmed Kamal
Daniel G. Tenen
Susumu S. Kobayashi

The CCAAT enhancer-binding protein α (C/EBPα) plays an important role in myeloid cell differentiation and in the enhancement of C/EBPα expression/activity, which can lead to granulocytic differentiation in acute myeloid leukemia (AML) cells. We found that styryl quin…

Source: MoleculesCategory: Chemistry Authors: Tags: Article Source Type: research

WT1 mRNA expression is a universal marker of MRD in patients with acute myeloid leukemia (AML). The aim of this retrospective study was to evaluate the ability of serial measurement of peripheral blood WT1 mRNA levels to predict relapse in patients with AML in remission.

Source: Clinical Lymphoma, Myeloma and LeukemiaCategory: Hematology Authors: Tags: Original Study Source Type: research

Erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, may have off-target activity inducing acute myeloid leukemia (AML) differentiation, possibly through SYK inhibition. We investigated erlotinib in a pilot phase II study for efficacy in relapsed/refractory AML patients at a dose of 150 mg once daily in 28-day cycles. Twenty-nine patients were treated for a median of 29 days (range 12 –142 days). Seven patients (24%) received #x3e; 1 cycle of therapy and 12 (41%) discontinued treatment before day 28 due to disease progression. One patient (3%) achieved complete remission and 2 (7%) a #x3e; 50% reduction i…

Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children, and the overall outcomes of this malignancy remain poor. Outside the blood stream and bone marrow, the skin is the most common site that is affected by this leukemia. In fact, leukemia manifest on the skin as erythematous, violaceus or hemorrhagic papules and/or nodules on the extremities, trunk and head, commonly known as leukemia cutis. The etiology for most cases of AML is unclear, but several risk factors including ionizing radiation, chemical exposure and genetic factors were implicated in leukemogenesis.

A 65-year-old woman with a history of acute myelogenous leukemia (AML) presented to the hospital with neutropenic fevers. An extensive infectious work up including urine and blood cultures was negative, and a CT scan of the chest demonstrated pulmonary nodules but without growth of infectious organisms on bronchoscopy. Despite continued broad-spectrum antibacterial and antifungal therapy the patient failed to defervesce. Dermatology was subsequently consulted regarding a worsening lesion on the left dorsal hand that had developed at the site of a previous blood draw.





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image